Aceso Life Science Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	7.5yrs
Board average tenure	11.8yrs

Recent management updates

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

CEO

Aceso Life Science Group has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chi Tak Fok	CFO & Executive Director	13.4yrs	HK$6.10m	0.82% HK$ 9.6m
Shao Yu Li	Senior Consultant	8.7yrs	HK$13.20m	57.52% HK$ 670.9m
Zhiliang Ou	Executive Director	no data	HK$600.00k	0.0099% HK$ 115.9k
Xiaodong Liu	Chief Operating Officer	5.7yrs	no data	no data
Chun Law	Group Financial Controller	7.5yrs	no data	no data
Chun Pong Siu	Company Secretary	1.8yrs	no data	no data

7.5yrs

Average Tenure

50yo

Average Age

Experienced Management: 474's management team is seasoned and experienced (7.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chi Tak Fok	CFO & Executive Director	10.7yrs	HK$6.10m	0.82% HK$ 9.6m
Zhiliang Ou	Executive Director	11.9yrs	HK$600.00k	0.0099% HK$ 115.9k
Kwan Sing Lam	Independent Non-Executive Director	11.8yrs	HK$200.00k	0.0099% HK$ 115.9k
Ming Sun Chan	Independent Non-Executive Director	12.2yrs	HK$200.00k	0.0099% HK$ 115.9k
Yiu Tong Mak	Independent Non-Executive Director	2.8yrs	HK$200.00k	no data

11.8yrs

Average Tenure

53yo

Average Age

Experienced Board: 474's board of directors are seasoned and experienced ( 11.8 years average tenure).

Aceso Life Science Group Management

Management criteria checks 2/4

Key information

Recent management updates

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Aceso Life Science Group Limited Announces Change of Company Secretary

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

Recent updates

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age